Clinical Trials Browser

Withdrawn × Triple Negative Breast Neoplasms × 1 year × Clear all

NCT07134556 2026-05-01

ADJUNCT

Phase 2 Withdrawn

Triple Negative Breast Neoplasms

NCT06229392 2026-03-11

A Study to Evaluate the Intratumoral Influenza Vaccine Administration in Patients With Breast Cancer

Phase 1 Withdrawn

Breast Neoplasms, Influenza, Human, Triple Negative Breast Neoplasms

NCT06829199 2026-02-19

MK-5890-003

Phase 2 Withdrawn

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT07226102 2026-02-04

Virtual Mental Health Intervention to Address Fear of Progression for Women With High Risk or Stage III-IV Gynecologic or Breast Cancer

Phase NA Withdrawn

BreastGynecologic

Genital Neoplasms, Female, Ovarian Neoplasms, Vaginal Neoplasms, Vulvar Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT06084689 2025-09-02

EMPIRE

Phase 2 Withdrawn

BreastGastrointestinalSarcomaThoracic

Tertiary Lymphoid Structures, Biliary Tract Neoplasms, Carcinoma, Non-Small-Cell Lung, Sarcoma, Colorectal Neoplasms, Triple Negative Breast Neoplasms

NCT06246786 2025-07-16

Breast/Cyclosporin A/TNBC (Triple Negative Breast Cancer)

Phase EARLY_PHASE1 Withdrawn

Triple Negative Breast Neoplasms

NCT06590558 2025-07-03

Testing the Addition of an Investigational Anti-Cancer Drug, ASTX660 (Tolinapant), to a Usual Chemotherapy Treatment (Eribulin) for Treatment of Advanced Triple Negative Breast Cancer

Phase 1 Withdrawn

Triple Negative Breast Neoplasms